Catalyst Wire Dossier Catalyst Wire Dossier

AAV gene therapy targeting CNGA3

AAV CNGA3 gene therapy · Beacon Therapeutics
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AAV gene therapy targeting CNGA3, covering 2022-07-22 to 2022-07-22. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial) [Phase 1, Phase 2]

See pricing